Biofrontera (BFRI) vs Karyopharm Therapeutics (KPTI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Biofrontera (BFRI) has outperformed Karyopharm Therapeutics (KPTI) over the past year, losing 9.0% versus a loss of 89.8%. Biofrontera is the larger company by market cap ($13.6 million vs $13.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BFRI | KPTI |
|---|---|---|
| Share price | $0.9188 | $0.60 |
| Market cap | $13.65M | $13.61M |
| 1-day change | -1.77% | -6.98% |
| YTD return | +61.19% | -91.85% |
| 1-year return | -9.03% | -89.83% |
| 5-year return | — | -99.28% |
| Forward P/E | 2.14 | — |
| EPS (TTM) | $-0.43 | $-14.33 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.66 | $10.99 |
| 52-week low | $0.555 | $0.60 |
| Distance from 52-week high | -44.65% | -94.54% |
| Analyst consensus | none | none |
| Avg. price target upside | +553.03% | +1108.33% |
| Average volume | 547.45K | 1.71M |
| Shares outstanding | 14.85M | 22.68M |
| Employees | 84 | 228 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BFRI has outperformed KPTI by 80.8 percentage points over the past year.
About Biofrontera
BFRI stock →Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions.
Healthcare · Drug Manufacturers - Specialty & Generic · 84 employees
About Karyopharm Therapeutics
KPTI stock →Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).
Healthcare · Biotechnology · 228 employees
BFRI vs KPTI FAQ
Which is bigger, Biofrontera or Karyopharm Therapeutics?
Biofrontera (BFRI) is larger, with a market capitalization of $13.65M compared with $13.61M for Karyopharm Therapeutics (KPTI).
Which stock has performed better over the past year, BFRI or KPTI?
BFRI returned -9.03% over the past 12 months, compared with -89.83% for KPTI (price return, excluding dividends). Past performance does not predict future results.
Are Biofrontera and Karyopharm Therapeutics in the same industry?
Both are in the Healthcare sector, but in different industries: Drug Manufacturers - Specialty & Generic for Biofrontera and Biotechnology for Karyopharm Therapeutics.